Levamisole/5-fluorouracil for colon cancer
Executive Summary
Drug combo has been shown to substantially reduce cancer recurrence rates, delay onset of tumor relapse and improve survival rates for patients following surgical treatment, according to study of 408 patients released by NCI Oct. 2. Treatment IND for combo was approved in May. 48% of patients treated with combo were alive five years after therapy compared to 37% who received no post-operative treatment. Study's principal investigator concluded that "the option of therapy with levamisole and 5-FU should be offered to almost all patients who have surgical treatment for high-risk, stage C [Duke's] colon cancer".
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.